TR study of ‘multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer"

ABSTRACT: Primary outcome(s): Cancer-related gene alteration, expression of protein, and expression of RNA

DISEASE(S): Colorectal Cancer

PROVIDER: 2645675 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR